Telix Current Deferred Revenue from 2010 to 2024
| TLX Stock | 15.15 0.45 3.06% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 112 M | Current Value 117.6 M | Quarterly Volatility 38.9 M |
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.1 M, Interest Expense of 7.1 M or Selling General Administrative of 57.5 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Invested Capital of 0.0. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
Telix | Current Deferred Revenue |
Latest Telix Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Telix Pharmaceuticals Limited over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Telix Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Telix Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 26,009,990 | |
| Geometric Mean | 12,716,405 | |
| Coefficient Of Variation | 149.44 | |
| Mean Deviation | 28,636,517 | |
| Median | 7,093,000 | |
| Standard Deviation | 38,868,911 | |
| Sample Variance | 1510.8T | |
| Range | 110.5M | |
| R-Value | 0.71 | |
| Mean Square Error | 802.4T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 6,187,564 | |
| Total Sum of Squares | 21151.1T |
Telix Current Deferred Revenue History
About Telix Pharmaceuticals Financial Statements
Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 112 M | 117.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.